TCM Biotech International Profit Margin

TCM Biotech International (4169.TWO) currently reports a profit margin of 2.97% as of December 2025. That compares with 2.08% in the prior-year period — up 43.0% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore TCM Biotech International's profit margin history and peer comparisons.

TCM Biotech International's profit margin increased from 2.08% to 2.97% — a 43.0% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

TCM Biotech International's profit margin of 2.97% is lower than the Healthcare sector average of 21.34%. That is roughly 86.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but TCM Biotech International's current 2.97% should be judged against Healthcare norms (sector average: 21.34%) and against 4169.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 2.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for TCM Biotech International, and consider following 4169.TWO for alerts when major investors trade the stock.